Concord Biotech
- Market Cap
- ₹11,470 Cr
- P/E
- 38.93
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 17.40%
- Debt to Equity
- 0.00
- EPS (TTM)
- ₹14.08
- Book Value
- ₹99.70
- Market Cap
- ₹11,470 Cr
- P/E (TTM)
- 38.93
- P/B
- 5.50
- ROE
- 13.00%
- Dividend Yield
- 1.36%
- EBITDA
- ₹420 Cr
- 52W High
- ₹807.50
- 52W Low
- ₹493.50
- Day Range
- ₹546.10 – ₹558.00
- Volume
- 1,28,839
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,884.90 | 41.25 | 4,52,251 | 5.07 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,180.50 | 88.26 | 2,96,807 | 16.49 | 0.27% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,689.50 | 77.80 | 1,78,374 | 9.71 | 0.82% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,294.60 | 92.52 | 1,23,980 | 20.45 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,200.00 | 28.63 | 1,19,700 | 4.30 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,390.20 | 41.44 | 1,16,037 | 2.99 | 0.57% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,415.00 | 39.45 | 1,14,312 | 3.23 | 0.92% | 11.60% | 15.50% | 28,139 | 2,855 | |
| 548.20 | 38.93 | 11,470 | 5.50 | 1.35% | 13.00% | 17.40% | 1,177 | 295 | |
| Median 8 companies | 1,649.95 | 41.35 | 1,21,840 | 5.29 | 0.70% | 16.25% | 17.60% | 22,770 | 2,808 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 68
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 53
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 24
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 84
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 24
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 53
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 28.2%
Weaknesses
2- The company has delivered a poor sales growth of 11.3% over past five years.
- Company has high debtors of 159 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 4 | 3 |
| Oscillators | Bullish | 2 | 4 | 3 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Bullish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 34.12
- Neutral
- MACD (12,26,9)
- −29.91
- Bearish
- SMA (50)
- 664.43
- Bearish
- SMA (200)
- 630.83
- Bearish
As of
Analyst Rating
2 of 3 analysts rate Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +14.35% |
|---|---|
| 5Y | +11.33% |
| 3Y | +7.34% |
| 1Y | −12.08% |
| TTM | +4.62% |
Net profit
| 10Y | +11.70% |
|---|---|
| 5Y | +2.28% |
| 3Y | +3.39% |
| 1Y | −29.49% |
| TTM | −8.39% |
Operating cash flow
| 10Y | — |
|---|---|
| 5Y | +9.59% |
| 3Y | +2.38% |
| 1Y | +7.76% |
| TTM | — |
10Y: The statements do not go back far enough for this window.
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −11.73 pp |
|---|---|
| 5Y | −17.43 pp |
| 3Y | −4.60 pp |
| 1Y | −6.52 pp |
| TTM | −3.34 pp |
Revenue by year
| Mar 2016 | ₹276 Cr |
|---|---|
| Mar 2018 | ₹340 Cr |
| Mar 2019 | ₹436 Cr |
| Mar 2020 | ₹512 Cr |
| Mar 2021 | ₹617 Cr |
| Mar 2022 | ₹713 Cr |
| Mar 2023 | ₹853 Cr |
| Mar 2024 | ₹1,017 Cr |
| Mar 2025 | ₹1,200 Cr |
| Mar 2026 | ₹1,055 Cr |
Net profit by year
| Mar 2016 | ₹87.00 Cr |
|---|---|
| Mar 2018 | ₹100 Cr |
| Mar 2019 | ₹118 Cr |
| Mar 2020 | ₹169 Cr |
| Mar 2021 | ₹235 Cr |
| Mar 2022 | ₹179 Cr |
| Mar 2023 | ₹238 Cr |
| Mar 2024 | ₹305 Cr |
| Mar 2025 | ₹373 Cr |
| Mar 2026 | ₹263 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Concord Biotech Ltd trades at ₹655.5 as of 2026-11-04 with a market cap of ₹12,834 crore and a PE of 24.33x. The company is virtually debt-free (debt-to-equity of 0) and has a long-term sales CAGR of 14% over 10 years, but recent performance shows a TTM sales decline of 6% and a TTM profit decline of 20%, placing the stock 19% below its 52-week high of ₹807.5.
- The company is essentially debt-free with a debt-to-equity ratio of 0, providing significant financial flexibility and resilience against interest rate cycles.
- 10-year compounded sales growth of 14% demonstrates a sustained long-term revenue expansion track record in the API and fermentation-based pharma segment.
- 10-year compounded profit growth of 11% indicates the company has been able to translate top-line growth into earnings over the long term.
- Healthy dividend payout ratio of 28.2% with a current dividend yield of 1.23% signals management's commitment to returning cash to shareholders despite being a growth-stage specialty pharma company.
- Return on equity averaged 18% over both 3-year and 5-year periods, reflecting efficient capital deployment relative to the zero-debt balance sheet.
- ROCE of 16.7% as of 2026-11-04 remains healthy for a healthcare company, suggesting the business generates reasonable returns on total capital employed.
- Price-to-book ratio of 3.3x is moderate for a debt-free specialty pharma company, and the stock trades 19% below its 52-week high of ₹807.5, which may reflect some correction from elevated levels.
- 5-year compounded sales growth of 11% outpaces the 3-year sales CAGR of 7%, suggesting the business scaled meaningfully over a broader horizon even if recent growth has moderated.
- TTM profit has declined 20%, a sharp reversal from the 10-year compounded profit growth of 11%, raising concerns about near-term earnings trajectory.
- TTM sales declined 6%, marking a contraction after years of positive growth and suggesting potential demand softness or pricing pressure in key segments.
- 3-year and 5-year compounded profit growth are both just 1%, indicating earnings have essentially stagnated over the medium term despite top-line expansion.
- Debtor days stand at 159, which is notably high and ties up significant working capital, increasing the risk of cash flow strain and potential bad debts.
- Last year's ROE of 13% has declined from the 3-year and 5-year average of 18%, suggesting deteriorating profitability and less efficient use of equity capital.
- The stock has delivered a 1-year price CAGR of -17%, underperforming broader indices and reflecting market scepticism about near-term fundamentals.
- 5-year sales CAGR of 11.3% is considered poor for a specialty pharma company in a high-growth market like India, potentially indicating competitive or structural limitations to scaling.
- PE of 24.33x on declining TTM earnings means the valuation may not fully reflect the recent downturn in profitability, as the earnings base itself is shrinking.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Concord Biotech successfully completed a 1:1 bonus share allotment, doubling its paid-up capital, which signals management confidence. However, the stock has been under pressure with a 14.28% decline over the past year and trading well below its 52-week high. The bonus issue and strong long-term returns from listing provide support, but near-term momentum remains weak. Investors should watch whether post-bonus trading stabilises or the downtrend continues.
- Stock down 14% over past year Nov 01
Concord Biotech shares have fallen 14.28% over the past year, with a 9.33% drop in one month and 6.97% decline in two weeks, indicating sustained selling pressure.
- Well below 52-week high Nov 01
Stock trading at ₹1,245.30, roughly 23% below its 52-week high of ₹1,614.05 hit on August 20, 2026.
- 1:1 bonus issue completed Nov 05
Concord Biotech allotted 10,46,16,204 bonus equity shares in a 1:1 ratio with record date November 4, doubling paid-up share capital to ₹20,92,32,408.
- 68% gains since listing Nov 01
Despite recent declines, stock remains up nearly 68% from its IPO issue price of ₹741 per share since its August 2023 listing.
- Pharma sector bullish sentiment Nov 01
Shares closed 1.25% higher at ₹1,245.30 amid overall bullish sentiment across pharmaceutical sector stocks during the week.
- Nov 4 bonus issue record date Nov 01
November 4 was set as the record date for the 1:1 bonus issue; investors needed to hold shares by November 3 to qualify.
- Market cap at ₹13,028 crore Nov 01
Concord Biotech maintains a market capitalisation of ₹13,027.86 crore with its 52-week low at ₹987.05 on April 2, 2026.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 261 | 312 |
| Expenses | 143 | 135 | 185 | 135 | 174 | 146 | 239 | 143 | 157 | 176 | 204 | 173 | 202 |
| Operating Profit | 119 | 106 | 134 | 81 | 137 | 98 | 190 | 61 | 91 | 102 | 122 | 87 | 110 |
| OPM % | 45% | 44% | 42% | 38% | 44% | 40% | 44% | 30% | 37% | 37% | 38% | 33% | 35% |
| Other Income | 8 | 8 | 11 | 10 | 10 | 15 | 9 | 14 | 13 | 7 | 16 | 13 | 10 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 | 19 | 19 | 18 | 18 |
| PBT | 113 | 100 | 131 | 78 | 133 | 99 | 185 | 57 | 86 | 90 | 118 | 82 | 102 |
| Tax % | 25% | 26% | 26% | 25% | 26% | 25% | 23% | 26% | 26% | 25% | 24% | 26% | 26% |
| Net Profit | 84 | 75 | 97 | 58 | 99 | 74 | 142 | 43 | 63 | 68 | 90 | 61 | 76 |
| EPS (₹) | 4.04 | 3.56 | 4.65 | 2.78 | 4.72 | 3.54 | 6.78 | 2.03 | 3.01 | 3.24 | 4.30 | 2.92 | 3.62 |
| YoY Sales growth | 65 | 0 | 17 | 11 | 18 | 1 | 35 | −5 | −20 | 14 | −24 | 28 | 26 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 239 | 276 | 340 | 436 | 512 | 617 | 713 | 853 | 1,017 | 1,200 | 1,055 | 1,177 |
| Expenses | 133 | 145 | 212 | 256 | 308 | 289 | 439 | 509 | 585 | 693 | 678 | 755 |
| Operating Profit | 105 | 131 | 127 | 180 | 205 | 328 | 274 | 344 | 432 | 507 | 377 | 422 |
| OPM % | 44% | 48% | 37% | 41% | 40% | 53% | 38% | 40% | 42% | 42% | 36% | 36% |
| Other Income | 11 | 8 | 36 | 17 | 31 | 14 | 23 | 35 | 34 | 44 | 49 | 46 |
| Interest | 1 | 0 | 1 | 1 | 1 | 1 | 6 | 5 | 3 | 1 | 1 | 0 |
| Depreciation | 10 | 10 | 18 | 19 | 21 | 28 | 50 | 54 | 54 | 54 | 74 | 75 |
| PBT | 106 | 129 | 144 | 178 | 213 | 313 | 241 | 320 | 409 | 496 | 351 | 393 |
| Tax % | 34% | 33% | 30% | 33% | 21% | 25% | 26% | 26% | 26% | 25% | 25% | — |
| Net Profit | 70 | 87 | 100 | 118 | 169 | 235 | 179 | 238 | 305 | 373 | 263 | 295 |
| EPS (₹) | 3.36 | 4.17 | 4.80 | 5.66 | 8.08 | 11.25 | 8.54 | 11.38 | 14.57 | 17.83 | 12.58 | 14.08 |
| Div. Payout % | 22% | 25% | 0% | 21% | 22% | 0% | 3% | 30% | 30% | 25% | 30% | — |
| Sales growth | — | 16 | — | 28 | 18 | 20 | 16 | 20 | 19 | 18 | −12 | 5 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 268 | 329 | 585 | 673 | 761 | 990 | 1,098 | 1,282 | 1,515 | 1,802 | 2,009 | 2,076 |
| Borrowings | 35 | 36 | 22 | 9 | 52 | 89 | 62 | 32 | 10 | 3 | 1 | 1 |
| Other Liabilities | 55 | 74 | 69 | 71 | 118 | 94 | 144 | 191 | 164 | 219 | 216 | 252 |
| Total Liabilities | 367 | 448 | 685 | 763 | 941 | 1,183 | 1,313 | 1,515 | 1,699 | 2,034 | 2,237 | 2,339 |
| Fixed Assets | 104 | 110 | 189 | 230 | 240 | 546 | 573 | 593 | 575 | 795 | 786 | 764 |
| CWIP | 19 | 70 | 3 | 19 | 141 | 18 | 74 | 173 | 211 | 51 | 79 | 112 |
| Investments | 42 | 43 | 151 | 229 | 199 | 142 | 74 | 138 | 244 | 335 | 488 | 535 |
| Other Assets | 202 | 225 | 343 | 285 | 361 | 477 | 592 | 611 | 668 | 854 | 883 | 928 |
| Total Assets | 367 | 448 | 685 | 763 | 941 | 1,183 | 1,313 | 1,515 | 1,699 | 2,034 | 2,237 | 2,339 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | — | — | 79 | — | 155 | 167 | 207 | 246 | 265 | 245 | 264 |
| Investing | — | — | −42 | — | −114 | −195 | −112 | −158 | −155 | −160 | −142 |
| Financing | — | — | −37 | — | −43 | 31 | −100 | −85 | −99 | −99 | −115 |
| Net Cash Flow | — | — | 0 | — | −1 | 3 | −4 | 3 | 12 | −14 | 7 |
| Free Cash Flow | — | — | 79 | — | −1 | −37 | 52 | 101 | 180 | 134 | 169 |
| CFO/EBITDA | — | — | 101 | — | 100 | 74 | 98 | 92 | 85 | 70 | 96 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 165 | 182 | 236 | 133 | 131 | 105 | 119 | 117 | 125 | 159 | 159 |
| Inventory Days | 276 | 321 | 381 | 310 | 312 | 503 | 434 | 430 | 331 | 286 | 483 |
| Days Payable | 108 | 129 | 210 | 112 | 201 | 152 | 185 | 190 | 150 | 135 | 150 |
| Cash Conversion Cycle | 334 | 374 | 407 | 331 | 242 | 456 | 368 | 357 | 306 | 310 | 492 |
| Working Capital Days | 195 | 209 | 275 | 177 | 159 | 177 | 163 | 153 | 166 | 193 | 231 |
| ROCE % | — | 37% | — | 25% | 25% | 32% | 21% | 26% | 28% | 28% | 17% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Concord Biotech insights
65 extracted metrics across FY15–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · Jun 2026Transcript PPT Recording
- Concall · May 2026PPT
- Q3 FY26 concall · Feb 2026Transcript PPT
- 23 Sep 2026
- 23 Jul 2025
- 9 May 2024
- 10 Apr 2023
- 7 Apr 2022
- General announcements 28 Oct 2026
Frequently Asked Questions about Concord Biotech
What does Concord Biotech Ltd do?
Where is Concord Biotech Ltd (CONCORDBIO) listed?
Which sector does Concord Biotech Ltd belong to?
What is the market capitalisation of Concord Biotech Ltd?
What is the PE ratio of Concord Biotech Ltd?
What is the 52-week high and low of Concord Biotech Ltd?
Does Concord Biotech Ltd pay dividends?
What is the Return on Equity (ROE) of Concord Biotech Ltd?
Company Information
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CONCORDBIO.md for Concord Biotech Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.